Product Name :
GSK-J1 — H3K27 Histone Demethylases UTX and JMJD3 Inhibitor
Description:
GSK-J1 is the first selective and potent inhibitor of the H3K27 histone demethylases UTX and JMJD3. H3K27 methylations play important roles in regulating gene expression through the polycomb-repressive complex (PRC1 or PRC2). This epigenetic mark can be demethylated by lysine demethylase (KDM) UTX and JMJD3, which play important roles in cellular differentiation, development and cancer. In relevant biological assays, GSK-J1 was shown to reduce lipopolysaccharide-induced pro-inflammatory cytokine production by human primary macrophages, a process that depends on both UTX and JMJD3. GSK-J1 represents a unique small molecule tool to allow selective pharmacological intervention across the JMJ family. Although critical for in vitro binding, the highly polar carboxylate group of GSK-J1 restricts its cellular permeability. Therefore another compound, GSK-J4, was developed as a pro-drug, masking the polarity of the acid group of the GSK-J1, for cellular assays.
CAS:
1373422-53-7
Molecular Weight:
389.45
Formula:
C22H23N5O2
Chemical Name:
3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
Smiles :
OC(=O)CCNC1=CC(=NC(=N1)C1=CC=CC=N1)N1CCC2=CC=CC=C2CC1
InChiKey:
AVZCPICCWKMZDT-UHFFFAOYSA-N
InChi :
InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
GSK-J1 is the first selective and potent inhibitor of the H3K27 histone demethylases UTX and JMJD3. H3K27 methylations play important roles in regulating gene expression through the polycomb-repressive complex (PRC1 or PRC2). This epigenetic mark can be demethylated by lysine demethylase (KDM) UTX and JMJD3, which play important roles in cellular differentiation, development and cancer. In relevant biological assays, GSK-J1 was shown to reduce lipopolysaccharide-induced pro-inflammatory cytokine production by human primary macrophages, a process that depends on both UTX and JMJD3. GSK-J1 represents a unique small molecule tool to allow selective pharmacological intervention across the JMJ family. Although critical for in vitro binding, the highly polar carboxylate group of GSK-J1 restricts its cellular permeability. Therefore another compound, GSK-J4, was developed as a pro-drug, masking the polarity of the acid group of the GSK-J1, for cellular assays.{{Fmoc-Cys(Trt)-OH} site|{Fmoc-Cys(Trt)-OH} {Amino Acid Derivatives}|{Fmoc-Cys(Trt)-OH} Purity & Documentation|{Fmoc-Cys(Trt)-OH} In Vivo|{Fmoc-Cys(Trt)-OH} manufacturer|{Fmoc-Cys(Trt)-OH} Autophagy} |Product information|CAS Number: 1373422-53-7|Molecular Weight: 389.45|Formula: C22H23N5O2|Related CAS Number:|2309668-29-7 (Lithium)|Chemical Name: 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid|Smiles: OC(=O)CCNC1=CC(=NC(=N1)C1=CC=CC=N1)N1CCC2=CC=CC=C2CC1|InChiKey: AVZCPICCWKMZDT-UHFFFAOYSA-N|InChi: InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)|Technical Data|Appearance: Solid Power.{{3-AP} web|{3-AP} DNA/RNA Synthesis|{3-AP} Protocol|{3-AP} Purity|{3-AP} manufacturer|{3-AP} Cancer} |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:23937941 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|GSK-J1 was used at 30-100 µM final concentration in vitro.|References:|Kruidenier L, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response (2012) Nature. 488(7411):404-8.SGC website: http://www.thesgc.org/scientists/chemical_probes/GSKJ1Products are for research use only. Not for human use.|Documents||